Anzeige
For her discovery, Neta Pessah received one of the prestigious Kaye Innovation Awards presented on June 9 during the Hebrew University Board of Governors meeting in Jerusalem.
Epilepsy is one of the most common neurological disorders, affecting about one percent of the world's population. Many new antiepileptic drugs have been introduced to the clinics recently, but despite the availability of these drugs, about 30 percent of the patients are still not seizure free.
Furthermore, many of the available drugs cause side effects, which can sometimes be fatal. One of the leading drugs for treating epilepsy and other neurological disorders is valproic acid (VPA). However, this drug has two life threatening side effects, liver toxicity and fetal malformation, that are related to the drug's chemical structure.
In Pessah’s ongoing research with VPA, she was successful in designing and synthesizing a new family of compounds based on a non-harmful analogue of that drug. Two of the compounds she formulated, Alpha-F-TMCD and Alpha-Cl-TMCD, were found to be highly potent as anticonvulsants without harmful side effects when tested on animal models. Alpha-Cl-TMCD is now under further testing at the National Institutes of Health in the United States.
Pessah says that her results suggest that these two novel compounds have high potential for development into new drugs to treat different types of epilepsy, neuropathic pain and other central nervous system disorders. The compounds have shown high potency, wide safety margins and lack of harmful effects on fetuses.
The Kaye Innovation Awards have been given annually since 1994. Isaac Kaye of England, a prominent industrialist in the pharmaceutical industry, established the awards to encourage faculty, staff and students of the Hebrew University to develop innovative methods and inventions with good commercial potential which will benefit the university and society.
Jerry Barach | Source: Hebrew University
Further information: www.huji.ac.il
Further Reports about: Alpha-Cl-TMCD > anti-epileptic drugs > AWARD > Hebrew University > Innovation Awards > neurological disorders > Valproic Acid > VPA
More articles from Awards Funding:
Award Ceremony Balzan Prizes 2009
23.11.2009 | Balzan Stiftung "Preis" - Mailand
Call for Entries: Public Asked to Submit Videos to 2010 Neuro Film Festival
19.11.2009 | American Academy of Neurology
First black holes may have incubated in giant, starlike cocoons
25.11.2009 | Physics and Astronomy
KfW issues its first ever 7 year Euro-Benchmark
25.11.2009 | Business and Finance
Intelligence inside metal components
25.11.2009 | Information Technology
Multidisciplinary meeting on Urological Cancers aims to benefit cancer patients
20.11.2009 | Event News
'Golden Age' for clinical psychology in Northern Ireland
20.11.2009 | Event News
New Perspectives in Marine Anti-Fouling Research
11.11.2009 | Event News